Page 2 - Divi's Laboratories

IT, pharma firms emerge Samvat 2076 winners; Infy, Divi's Lab top gainers

On the other hand, PSU stocks and banks have been laggards - with ONGC, Indian Oil, IndusInd Bank, and Coal India delivering the worst returns.

This India-focused fund beating 98% of peers targets crisis winners

According to the fund's profile, its top holding as of July 31 was drugmaker Divi's Laboratories Ltd., which has gained more than 70% in 2020

Divi's Laboratories, SBI Life Insurance shares gain on Nifty inclusion

Shares of Zee Entertainment Enterprises fell 3.7 per cent and that of Bharti Infratel ended flat. The two companies will be removed from the bluechip index

Divi's, SBI Life to see combined inflows of Rs 1,400 cr on Nifty inclusion

Over Rs 650-cr selling in Zee, Infratel

Divi's Labs: APIs, custom synthesis, ongoing capex plan to support growth

The near term upside, however, is limited given the sharp stock price run up

Nifty rejig announcement: Divi's Lab hits all-time high, SBI Life gains 4%

For the quarter ended June 2020, Divi's Lab reported a net profit of Rs 492.06 crore on account of robust sales.

SBI Life, Divi's Laboratories to move in Nifty 50 index from Sept 25

Bharti Infratel and Zee Entertainment Enterprises will be dropped from the Nifty 50, NSE Indices said in a statement

Divi's Laboratories: Margins likely to remain subdued, say analysts

Margins to get better once supplies start from expanded capacities next year

Divi's Labs Q4 net profit up 33%, total income stands at Rs 1,466 cr

The company had posted a net profit of Rs 291.97 crore for the same period previous fiscal, Divi's Labs said in a BSE filing

Divi's Labs Q2 net down 12% at Rs 357 cr; revenue rises to Rs 1446 cr

The company had posted a net profit of Rs 403.72 crore in the July-September period of 2018-19.

Divi's Labs cash in on bullish sentiment, strong growth prospects

The second largest pharma player by market value is also expanding capacities to push earnings

At Rs 58.8 cr, Murali of Divi's Lab highest paid pharma honcho in FY19

According to Divis latest annual report, Murali Divi, the promoter-executive,was given a hike of 46.3 per cent in his remuneration over the previous fiscal

Income-Tax department raids drug firm Divi's Laboratories premises

The company said the raids were conducted by the officials of Income-Tax Department under Section 132 of the Income-Tax Act

Divi's Labs hits new high; soars 26% in three weeks on strong Q2 results

The stock hit a new high of Rs 1,574, up 3% on the BSE today.

With revenues, profit set to increase, re-rating ahead for Divi's Labs

Analysts have upgraded estimates on supply disruption, weak rupee

Divi's Labs gains 4% on successful USFDA inspection of Telangana unit

The stock was up 4% to Rs 1,213 on the BSE in early morning deal, trading close to its 52-week high of Rs 1,220 touched on May 11, 2018.

Divi's Laboratories Vizag unit receives USFDA EIR with six observations

The USFDA releases a copy of the EIR to the establishment that was the subject of an FDA inspection

Divi's Labs surges 21% as USFDA to lift import alert for Visakhapatnam unit

The stock surged 21% to Rs 1,117 on the BSE in early morning trade on back of nearly four-fold jump in trading volumes.

Divi's Labs surges 6% on successful USFDA inspection of Unit-2

The stock trading at its highest level since December 23, 2016, has outperformed the market by surging 47% in past one month, as compared to 4% rise in Sensex.

Divi's Laboratories: High on hopes

Positive outcome of ongoing plant inspection can lead to more gains